BRIGHAM AND WOMEN'S HOSPITAL
Cell type-directed Tim-3 targeting in melanoma
Cell type-directed Tim-3 targeting in melanoma is a funding opportunity from BRIGHAM AND WOMEN'S HOSPITAL, up to 580194, closing May 31, 2027.
May 31, 2027
(304d left)Overview
PROJECT SUMMARY Immune checkpoint blockade has elicited unprecedented clinical responses in patients with metastatic melanoma and other cancers. A promising new checkpoint under investigation in cancer therapeutic trials is T- cell immunoglobulin and mucin domain 3 (Tim-3). Tim-3 blockade reverses T-cell impairment,…